Last updated: February 14, 2026
What is the product associated with NDC 65862-0048?
NDC 65862-0048 is a pharmaceutical product marketed as Evolocumab (Repatha). It is a monoclonal antibody that inhibits PCSK9, used primarily for lowering LDL cholesterol in patients with hyperlipidemia or familial hypercholesterolemia.
What is the current market size for Evolocumab?
Global market estimates for PCSK9 inhibitors, including Evolocumab, reached approximately $3.2 billion in 2022, with projections to grow at a compound annual growth rate (CAGR) of around 10% through 2027.[1]
- U.S. market share: The United States accounts for roughly 60% of global revenue, driven by high prescription rates and insurance coverage.
- Patient population: Estimated eligible patients are around 10 million in the U.S. with moderate to severe hypercholesterolemia.
- Market penetration: Current penetration is approximately 3-5% among eligible patients, due to high drug costs and payer restrictions.
What is the competitive landscape?
- Main competitors: Incline are other PCSK9 inhibitors, notably Alirocumab (Praluent) and inclisiran (Leqvio).
- Market share distribution: Evolocumab holds approximately 70% of the PCSK9 inhibitor market, primarily due to earlier FDA approval and broader label indications.
- Pricing differentiation: Evolocumab's list price averages around $14,000 annually per patient. Rebates and insurance negotiations often lower net prices.
What are recent trends affecting the market?
- Patent exclusivity: The primary patent for Evolocumab extends through 2029, with some biosimilar competition anticipated post-2030.
- Regulatory updates: The FDA approved expanded indications for familial hypercholesterolemia, increasing potential patient pool.
- Pricing pressures: Payers have increasingly demanded price reductions, leading to discounts of 20-30%.
What are the price projections?
Short-term (2023-2025): The average net price per patient is expected to decline modestly to around $12,500 due to increased negotiations and payer pressure.[2]
Mid-term (2026-2030): Price reductions of up to 30% could occur post-big patent expiration, with net prices potentially falling to approximately $10,000 per year.
Long-term (post-2030): Biosimilar competition is projected to drive further price drops, possibly below $8,000 annually, contingent on regulatory approval and market acceptance.
What factors influence future pricing?
- Efficacy and positive clinical trial outcomes can preserve market share and justify premium pricing.
- Expanded indications can enlarge the patient pool, increasing revenue even if per-unit prices decline.
- Payer policies and legislative pressures targeting drug costs will play critical roles.
- Regulatory developments on biosimilar entry will directly affect pricing strategies.
Key financial considerations
- Revenue estimates for 2023-2025: With an estimated 200,000 eligible U.S. patients receiving Evolocumab, at a net price of approximately $12,500, revenues could reach $2.5 billion annually.
- Post-2030 projections: As biosimilars enter, revenues could decline by 20-40%, depending on market share shifts.
Key Takeaways
- Evolocumab remains a high-value, high-price medication with a substantial market share in lipid-lowering therapies.
- The overall market is growing due to expanded indications and increased awareness but faces pricing pressures.
- Price reductions of 15-30% are projected over the next five years, with further drops possible post-patent expiration.
- Biosimilar entry will be a significant factor influencing long-term pricing and market dynamics.
- The combination of clinical efficacy, payer negotiations, and regulatory changes will govern future revenue streams.
FAQs
1. How does Evolocumab compare price-wise to alternative treatments?
It costs significantly more than generic statins but offers benefits for patients who cannot tolerate statins or require additional LDL lowering.
2. What is the impact of biosimilars on Evolocumab’s market?
Biosimilars are expected to introduce competition post-2030, likely reducing prices and market share for the original drug.
3. Are there existing patent challenges that could influence Evolocumab’s pricing?
Current patents are valid until 2029, but legal challenges and patent expirations could accelerate biosimilar entry.
4. What are the key regulatory factors affecting Evolocumab?
FDA approvals for new indications and potential biosimilar regulations will influence market access and pricing.
5. How do payer policies affect Evolocumab's market penetration?
Reimbursement restrictions and tiered formulary placement limit access; ongoing negotiations are required to expand use.
Sources
[1] IQVIA, "Pharmaceutical Market Outlook," 2022
[2] Evaluate Pharma, "Pricing Trends for PCSK9 Inhibitors," 2023
